Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for shares of Zevra ...
Zevra Therapeutics (NASDAQ:ZVRA – Free Report) had its target price boosted by Canaccord Genuity Group from $23.00 to $25.00 ...
22h
Karan Kapoor, a managing director at Cantor Fitzgerald's investment banking division, spearheads the global tech investment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback